Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide

Nicholas Devito, Michael Yu, Ren Chen, Edward Pan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Metastatic melanoma is the second most common cancer to metastasize to the brain. It is typically treated using stereotactic radiosurgery with or without whole-brain radiation (WBR) therapy. Recently, the alkylating agent temozolomide, which has demonstrated activity in patients with brain metastasis and primary tumors, was used alongside WBR to delay brain metastasis recurrence, increase survival, and improve quality-of-life in patients with brain metastases. Patients and Methods: In this retrospective study, we reviewed outcomes of 29 patients treated from 2005-2009 at the Moffitt Cancer Center with brain metastases of melanoma. Results were narrowed via retrospective chart analysis to a cohort with brain metastasis receiving concomitant temozolomide and WBR. Results: Median progression-free survival was 20.4 weeks and overall survival was 44.4 weeks compared to 16 week survival of patients treated with WBR alone. Conclusion: A prospective trial evaluating this combined regimen may be considered.

Original languageEnglish (US)
Pages (from-to)4537-4543
Number of pages7
JournalAnticancer Research
Volume31
Issue number12
StatePublished - Dec 2011

Fingerprint

temozolomide
Melanoma
Retrospective Studies
Radiation
Neoplasm Metastasis
Brain
Survival
Radiosurgery
Alkylating Agents

Keywords

  • Brain metastases
  • Melanoma
  • Metastastic melanoma
  • Temozolomide
  • Whole-brain radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. / Devito, Nicholas; Yu, Michael; Chen, Ren; Pan, Edward.

In: Anticancer Research, Vol. 31, No. 12, 12.2011, p. 4537-4543.

Research output: Contribution to journalArticle

@article{2a7c05029a7f4031b64ce422808dc73d,
title = "Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide",
abstract = "Background: Metastatic melanoma is the second most common cancer to metastasize to the brain. It is typically treated using stereotactic radiosurgery with or without whole-brain radiation (WBR) therapy. Recently, the alkylating agent temozolomide, which has demonstrated activity in patients with brain metastasis and primary tumors, was used alongside WBR to delay brain metastasis recurrence, increase survival, and improve quality-of-life in patients with brain metastases. Patients and Methods: In this retrospective study, we reviewed outcomes of 29 patients treated from 2005-2009 at the Moffitt Cancer Center with brain metastases of melanoma. Results were narrowed via retrospective chart analysis to a cohort with brain metastasis receiving concomitant temozolomide and WBR. Results: Median progression-free survival was 20.4 weeks and overall survival was 44.4 weeks compared to 16 week survival of patients treated with WBR alone. Conclusion: A prospective trial evaluating this combined regimen may be considered.",
keywords = "Brain metastases, Melanoma, Metastastic melanoma, Temozolomide, Whole-brain radiation",
author = "Nicholas Devito and Michael Yu and Ren Chen and Edward Pan",
year = "2011",
month = "12",
language = "English (US)",
volume = "31",
pages = "4537--4543",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide

AU - Devito, Nicholas

AU - Yu, Michael

AU - Chen, Ren

AU - Pan, Edward

PY - 2011/12

Y1 - 2011/12

N2 - Background: Metastatic melanoma is the second most common cancer to metastasize to the brain. It is typically treated using stereotactic radiosurgery with or without whole-brain radiation (WBR) therapy. Recently, the alkylating agent temozolomide, which has demonstrated activity in patients with brain metastasis and primary tumors, was used alongside WBR to delay brain metastasis recurrence, increase survival, and improve quality-of-life in patients with brain metastases. Patients and Methods: In this retrospective study, we reviewed outcomes of 29 patients treated from 2005-2009 at the Moffitt Cancer Center with brain metastases of melanoma. Results were narrowed via retrospective chart analysis to a cohort with brain metastasis receiving concomitant temozolomide and WBR. Results: Median progression-free survival was 20.4 weeks and overall survival was 44.4 weeks compared to 16 week survival of patients treated with WBR alone. Conclusion: A prospective trial evaluating this combined regimen may be considered.

AB - Background: Metastatic melanoma is the second most common cancer to metastasize to the brain. It is typically treated using stereotactic radiosurgery with or without whole-brain radiation (WBR) therapy. Recently, the alkylating agent temozolomide, which has demonstrated activity in patients with brain metastasis and primary tumors, was used alongside WBR to delay brain metastasis recurrence, increase survival, and improve quality-of-life in patients with brain metastases. Patients and Methods: In this retrospective study, we reviewed outcomes of 29 patients treated from 2005-2009 at the Moffitt Cancer Center with brain metastases of melanoma. Results were narrowed via retrospective chart analysis to a cohort with brain metastasis receiving concomitant temozolomide and WBR. Results: Median progression-free survival was 20.4 weeks and overall survival was 44.4 weeks compared to 16 week survival of patients treated with WBR alone. Conclusion: A prospective trial evaluating this combined regimen may be considered.

KW - Brain metastases

KW - Melanoma

KW - Metastastic melanoma

KW - Temozolomide

KW - Whole-brain radiation

UR - http://www.scopus.com/inward/record.url?scp=84855161455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855161455&partnerID=8YFLogxK

M3 - Article

C2 - 22199328

AN - SCOPUS:84855161455

VL - 31

SP - 4537

EP - 4543

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -